Insights

The Future of Gene Therapies: Three Trends

“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...

A Patient Centric Approach to Clinical Research is Key for Product Development

Ensuring a patient centric approach during clinical research is vitally important to research sponsors and their partners. A clinical research site that...

The FDA and AAV-Based Gene Therapy Safety: What You Should Know

Science fiction author Arthur C. Clarke once commented that “Any sufficiently advanced technology is indistinguishable from magic.” Over the last couple of...

Patient Engagement – What History Teaches Us About Pharma’s Future Evolution

The pharmaceutical industry continues to grow by leaps and bounds. Advancements are happening on a weekly basis. But every time we take...

Monoclonal Antibodies Offer Much Needed Protection for the Immunocompromised Population

Even though we don’t feel it or notice it, each minute, our bodies’ immune systems are hard at work eliminating abnormal cells,...

OMNICHANNEL ORCHESTRATION IS MORE THAN JUST THE NEXT BEST ACTIONS

Omnichannel orchestration is critical to delivering a customized and relevant experience to each customer. If designed and executed correctly, responsive omnichannel marketing...

The Evolution of Treatment: Use of Anticoagulation in Cancer Patients

Cancer patients face many heightened health risks after their initial diagnosis. While the disease itself is a leading cause of death worldwide,...

Prostate Cancer Awareness – Men’s Health

While Prostate Cancer (PC) Awareness Month is behind us, the impact of this deadly scourge is not – in fact, it’s pervasiveness...

Latest news

Phase 2/3 of Athira Trial for Alzheimer’s Fails

Athira Pharma’s Phase 2/3 Alzheimer’s disease trial has ended in failure. The trial revealed that fosgonimeton performed no better...

Sanofi’s Tolebrutinib faces defeat in 2 out of 3 phase 3 MS trials

Sanofi has announced that tolebrutinib, a BTK inhibitor, failed in two out of three Phase 3 trials. Tolebrutinib was...

Illumina Gets Favorable Decision Regarding Grail Acquisition

In a decision expected to limit Brussels' merger authority, American gene sequencing firm Illumina prevailed in court against the...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Life Sciences Voice Top Five Newsletter

This week we take a look at...

Bayer Banks on Kerendia’s Potential in Heart Failure Space

Kerendia (finerenone), manufactured by Bayer and approved...

Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient

Neuralink, founded by Elon Musk, revealed that it has...